{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Title: Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients with Sepsis TheBLING III Randomized Clinical Trial\n",
      "\n",
      "Heading: Clinical Question\n",
      "List Items:\n",
      "- In critically ill adult patients with presumed sepsis, does the administration of β-lactam antibiotics via a continuous infusion compared to an intermittent infusion reduce 90-day mortality?\n",
      "\n",
      "Heading: Background\n",
      "List Items:\n",
      "- β-lactam antibiotics have time-dependent bactericidal activity\n",
      "- It is hypothesised that improved antibiotic exposure with continuous infusion will lead to longer time above MIC, with potentially improved bacterial eradication\n",
      "- Additionally, underdosing may occur in sepsis due to:Increased cardiac output with potentially increased drug clearanceCapillary leak and increased volume of distribution\n",
      "- Increased cardiac output with potentially increased drug clearance\n",
      "- Capillary leak and increased volume of distribution\n",
      "- BLING II(2015) showed no difference in alive ICU-free days at day 28 between continuous and intermittent administration of β-lactam antibiotics\n",
      "- MERCY(2023) showed a non-significant 2% reduction in mortality in with continuous infusions of Meropenem\n",
      "\n",
      "Heading: Design\n",
      "List Items:\n",
      "- Multicentre, multinational randomised controlled trial\n",
      "- Randomisation 1:1 via an online minimisation algorithmStratified by study site\n",
      "- Stratified by study site\n",
      "- Open label\n",
      "- Power calculation guided by BLING IISample size of 7000 required to achieve 90% power to detect 3.5% difference in all-cause mortality at 90 days including 5% loss to follow upAssumption of baseline mortality of 27.5%, at α of 0.05\n",
      "- Sample size of 7000 required to achieve 90% power to detect 3.5% difference in all-cause mortality at 90 days including 5% loss to follow up\n",
      "- Assumption of baseline mortality of 27.5%, at α of 0.05\n",
      "- Modified intention-to-treat analysis for primary end point\n",
      "- Prespecified adjusted analysis accounting for sex, APACHE II score, source of admission (emergency vs elective surgery vs other), type of β-lactam antibiotics used before randomisation\n",
      "- 5 pre-specified subgroups: Pulmonary infection, β-lactam antibiotic, Age (< or > 65), Sex, APACHE II score (< or > 25)\n",
      "- Clinical cure defined as completion of β-lactam antibiotic by day 14 without recommencement of antibiotics within 48hrs of cessation for same infective episode (investigator assessment of clinical response)\n",
      "- Independent DSMB conducted pre-specified midpoint safety analysis\n",
      "\n",
      "Heading: Setting\n",
      "List Items:\n",
      "- 104 intensive care units in 7 countries:Australia (25) / New Zealand (6) / UK (55) / Belgium (8) / France (5) / Sweden (3) / Malaysia (2)\n",
      "- Australia (25) / New Zealand (6) / UK (55) / Belgium (8) / France (5) / Sweden (3) / Malaysia (2)\n",
      "- Recruitment from March 2018 – January 2023\n",
      "\n",
      "Heading: Population\n",
      "List Items:\n",
      "- Inclusion:\n",
      "- Adults in ICU withDocumented site/strong suspicion of infection≥1 organ dysfunction criteria met in previous 24hrsTreatment with piperacillin-tazobactam or meropenem commenced within prior 24hrsExpected to remain in ICU for at least the next calendar day\n",
      "- Documented site/strong suspicion of infection\n",
      "- ≥1 organ dysfunction criteria met in previous 24hrs\n",
      "- Treatment with piperacillin-tazobactam or meropenem commenced within prior 24hrs\n",
      "- Expected to remain in ICU for at least the next calendar day\n",
      "- Exclusion:Receipt of piperacillin-tazobactam or meropenem for more than 24hrs during current infectious episodePatient known or suspected to be pregnantKnown allergy to piperacillin-tazobactam, meropenem or penicillinRequiring renal replacement therapy (acute or chronic)Previously enrolled in BLING IIIPalliative treatment only, limits to care, death is imminent, or death is likely within 90 days due to underlying process\n",
      "- Receipt of piperacillin-tazobactam or meropenem for more than 24hrs during current infectious episode\n",
      "- Patient known or suspected to be pregnant\n",
      "- Known allergy to piperacillin-tazobactam, meropenem or penicillin\n",
      "- Requiring renal replacement therapy (acute or chronic)\n",
      "- Previously enrolled in BLING III\n",
      "- Palliative treatment only, limits to care, death is imminent, or death is likely within 90 days due to underlying process\n",
      "- 29042 patients screened → 7202 randomised3595 to receive continuous antibiotics3607 to receive intermittent antibiotics\n",
      "- 3595 to receive continuous antibiotics\n",
      "- 3607 to receive intermittent antibiotics\n",
      "- Comparing baseline characteristics of continuous vs. intermittent groupAge: 59.3 vs 59.6 yearsMale: 66 vs 65 %APACHE II: 19.6 vs 19.5Inotropes/vasopressors in 24hr prior to randomisation: 71 vs 70 %Received antibiotics in 24hr prior to randomisation: 67 vs 70 %Source of admission:ED: 34 vs 33 %Wards: 28 vs 30 %OT post emergency surgery: 21 vs 20 %Primary site of infection:Pulmonary 59 vs 60 %Intra-abdominal 13 vs 13 %Blood 8 vs 8 %\n",
      "- Age: 59.3 vs 59.6 years\n",
      "- Male: 66 vs 65 %\n",
      "- APACHE II: 19.6 vs 19.5\n",
      "- Inotropes/vasopressors in 24hr prior to randomisation: 71 vs 70 %\n",
      "- Received antibiotics in 24hr prior to randomisation: 67 vs 70 %\n",
      "- Source of admission:ED: 34 vs 33 %Wards: 28 vs 30 %OT post emergency surgery: 21 vs 20 %\n",
      "- ED: 34 vs 33 %\n",
      "- Wards: 28 vs 30 %\n",
      "- OT post emergency surgery: 21 vs 20 %\n",
      "- Primary site of infection:Pulmonary 59 vs 60 %Intra-abdominal 13 vs 13 %Blood 8 vs 8 %\n",
      "- Pulmonary 59 vs 60 %\n",
      "- Intra-abdominal 13 vs 13 %\n",
      "- Blood 8 vs 8 %\n",
      "\n",
      "Heading: Intervention\n",
      "List Items:\n",
      "- Continuous infusion of β-lactam antibiotic (for clinician prescribed duration OR until ICU discharge)\n",
      "- Infusion over 24 hours began with a bolus of intermittent dose as a loadDuration: median 5.8 daysCumulative Dose: median 72 g (40.5 – 108) of Piperacillin-Tazobactam, and 17g (9 – 29) of meropenem\n",
      "- Duration: median 5.8 days\n",
      "- Cumulative Dose: median 72 g (40.5 – 108) of Piperacillin-Tazobactam, and 17g (9 – 29) of meropenem\n",
      "\n",
      "Heading: Control\n",
      "List Items:\n",
      "- Intermittent infusion of β-lactam antibiotic\n",
      "- Infusion over 30minsDuration: median 5.7 daysCumulative Dose: median 70.8 g (40.5 – 103.5) of Piperacillin-Tazobactam, and 16.0g (8.0 – 28.0) of meropenem\n",
      "- Duration: median 5.7 days\n",
      "- Cumulative Dose: median 70.8 g (40.5 – 103.5) of Piperacillin-Tazobactam, and 16.0g (8.0 – 28.0) of meropenem\n",
      "\n",
      "Heading: Outcome\n",
      "List Items:\n",
      "- Primary outcomeNo significant difference in all-cause mortality at day 90:24.9% (continuous) vs 26.8% (intermittent)Absolute difference -1.9% (95% CI -4.9 to 1.1)OR 0.91 (95% CI 0.81 to 1.01), p = 0.08Note that for adjusted analysis absolute difference -2.2% (95% CI -5.5 to 1.1)OR 0.89 (95% CI 0.79 – 0.99), p = 0.04\n",
      "- No significant difference in all-cause mortality at day 90:24.9% (continuous) vs 26.8% (intermittent)Absolute difference -1.9% (95% CI -4.9 to 1.1)OR 0.91 (95% CI 0.81 to 1.01), p = 0.08Note that for adjusted analysis absolute difference -2.2% (95% CI -5.5 to 1.1)OR 0.89 (95% CI 0.79 – 0.99), p = 0.04\n",
      "- 24.9% (continuous) vs 26.8% (intermittent)Absolute difference -1.9% (95% CI -4.9 to 1.1)OR 0.91 (95% CI 0.81 to 1.01), p = 0.08\n",
      "- Absolute difference -1.9% (95% CI -4.9 to 1.1)\n",
      "- OR 0.91 (95% CI 0.81 to 1.01), p = 0.08\n",
      "- Note that for adjusted analysis absolute difference -2.2% (95% CI -5.5 to 1.1)OR 0.89 (95% CI 0.79 – 0.99), p = 0.04\n",
      "- OR 0.89 (95% CI 0.79 – 0.99), p = 0.04\n",
      "- Secondary outcomes:\n",
      "- Comparing continuous vs intermittent infusion\n",
      "- Significantly greater in intervention group:Clinical cure: 55.7% vs 50.0%Absolute difference 5.7% (95% CI 2.4 to 9.1), p < 0.001OR 1.26 (95% CI 1.15 – 1.38)\n",
      "- Clinical cure: 55.7% vs 50.0%Absolute difference 5.7% (95% CI 2.4 to 9.1), p < 0.001OR 1.26 (95% CI 1.15 – 1.38)\n",
      "- Absolute difference 5.7% (95% CI 2.4 to 9.1), p < 0.001\n",
      "- OR 1.26 (95% CI 1.15 – 1.38)\n",
      "- No significant difference in:New acquisition/colonisation/infection with MRO or C Difficile: 7.2 vs 7.5%Absolute difference -0.3% (95% CI -1.9 to 1.4) p = 0.65All-cause ICU mortality: 17.1 vs 18.4%Absolute difference -1.3% (95% CI -4 to 1.4) p = 0.35All-cause hospital mortality: 23.3 vs 25 %Absolute difference -1.8% (95% CI -4.8 to 1.2) p = 0.27Days alive and free of ICU, hospital, mechanical ventilation or RRT by day 90\n",
      "- New acquisition/colonisation/infection with MRO or C Difficile: 7.2 vs 7.5%Absolute difference -0.3% (95% CI -1.9 to 1.4) p = 0.65\n",
      "- Absolute difference -0.3% (95% CI -1.9 to 1.4) p = 0.65\n",
      "- All-cause ICU mortality: 17.1 vs 18.4%Absolute difference -1.3% (95% CI -4 to 1.4) p = 0.35\n",
      "- Absolute difference -1.3% (95% CI -4 to 1.4) p = 0.35\n",
      "- All-cause hospital mortality: 23.3 vs 25 %Absolute difference -1.8% (95% CI -4.8 to 1.2) p = 0.27\n",
      "- Absolute difference -1.8% (95% CI -4.8 to 1.2) p = 0.27\n",
      "- Days alive and free of ICU, hospital, mechanical ventilation or RRT by day 90\n",
      "- Subgroups:All point estimates favoured continuous infusion but none statistically significant\n",
      "- All point estimates favoured continuous infusion but none statistically significant\n",
      "- Adverse Events:0.3% in continuous group vs 0.2% in intermittent group\n",
      "- 0.3% in continuous group vs 0.2% in intermittent group\n",
      "\n",
      "Heading: Authors’ Conclusions\n",
      "List Items:\n",
      "- The observed difference in 90-day mortality between continuous vs intermittent infusions of β-lactam antibiotics did not meet statistical significance in the primary analysis. However, the confidence interval around the effect estimate includes the possibility of both no important effect and a clinically important benefit in the use of continuous infusions in this group of patients\n",
      "\n",
      "Heading: Strengths\n",
      "List Items:\n",
      "- Extremely large RCT with robust internal and external validityDetailed screening log with a majority of those screened but not enrolled meeting exclusion criteria or declining to take partLarge number of centres across multiple countriesBalanced baseline characteristics – similar organisms cultured, baseline antibiotic useDoses and duration of antibiotics similar between groups (eTable 7, eFigure 1 and eFigure 2)\n",
      "- Detailed screening log with a majority of those screened but not enrolled meeting exclusion criteria or declining to take part\n",
      "- Large number of centres across multiple countries\n",
      "- Balanced baseline characteristics – similar organisms cultured, baseline antibiotic use\n",
      "- Doses and duration of antibiotics similar between groups (eTable 7, eFigure 1 and eFigure 2)\n",
      "- Detailed collection of infection site and antimicrobial data (eTable 3 – 6, 9)\n",
      "- Minimal loss to follow up\n",
      "\n",
      "Heading: Weaknesses\n",
      "List Items:\n",
      "- Unblinded\n",
      "- Dosing reverted to intermittent pre and post ICU – this may bias results towards the null\n",
      "- No consensusas to definition of clinical cure:Whilst the definition used in this trial is pragmatic and objective, is 48 hours long enough following cessation of antimicrobials to say clinical cure has been achieved?\n",
      "- Whilst the definition used in this trial is pragmatic and objective, is 48 hours long enough following cessation of antimicrobials to say clinical cure has been achieved?\n",
      "- Potential that patients with non-infectious causes of organ dysfunction are included\n",
      "- No reporting on therapeutic dose monitoring, or sensitivities / susceptibilities\n",
      "- Approximately 1/3rd of patients had a protocol violation (eTable 12):34% (continuous) vs 32% (intermittent) of patientsA large proportion were related to administration or dosing, of which the largest contributor was a pause or delay for > 1 hour:15.3% (continuous) and 22.6% (intermittent)\n",
      "- 34% (continuous) vs 32% (intermittent) of patients\n",
      "- A large proportion were related to administration or dosing, of which the largest contributor was a pause or delay for > 1 hour:15.3% (continuous) and 22.6% (intermittent)\n",
      "- 15.3% (continuous) and 22.6% (intermittent)\n",
      "\n",
      "Heading: The Bottom Line\n",
      "List Items:\n",
      "- In adult ICU patients with sepsis, continuous infusions should be commenced if IV access is available, given potential for benefit alongside no evidence for harm\n",
      "- I will be interested to see the results of any economic analyses or work into the impact of continuous infusions on bedside workload\n",
      "\n",
      "Heading: Leave a ReplyCancel reply\n",
      "List Items:\n",
      "- synergy physiotherapycliniconTEAM\n",
      "- Anand SwaminathanonANNEXA-I – Andexanet for Factor Xa Inhibitor–Associated ICH\n",
      "- Stuart McLayonNICO – Noninvasive Airway Management of Comatose Patients with Acute Poisoning\n",
      "- David SlessoronHEMOTION – transfusion thresholds in TBI\n",
      "- SBA 19 – FFICM PreponPROSEVA\n",
      "\n",
      "Heading: Search TBL\n",
      "List Items:\n",
      "- synergy physiotherapycliniconTEAM\n",
      "- Anand SwaminathanonANNEXA-I – Andexanet for Factor Xa Inhibitor–Associated ICH\n",
      "- Stuart McLayonNICO – Noninvasive Airway Management of Comatose Patients with Acute Poisoning\n",
      "- David SlessoronHEMOTION – transfusion thresholds in TBI\n",
      "- SBA 19 – FFICM PreponPROSEVA\n",
      "\n",
      "Heading: Clinical Topics\n",
      "List Items:\n",
      "- synergy physiotherapycliniconTEAM\n",
      "- Anand SwaminathanonANNEXA-I – Andexanet for Factor Xa Inhibitor–Associated ICH\n",
      "- Stuart McLayonNICO – Noninvasive Airway Management of Comatose Patients with Acute Poisoning\n",
      "- David SlessoronHEMOTION – transfusion thresholds in TBI\n",
      "- SBA 19 – FFICM PreponPROSEVA\n",
      "\n",
      "Heading: Year of Publication\n",
      "List Items:\n",
      "- synergy physiotherapycliniconTEAM\n",
      "- Anand SwaminathanonANNEXA-I – Andexanet for Factor Xa Inhibitor–Associated ICH\n",
      "- Stuart McLayonNICO – Noninvasive Airway Management of Comatose Patients with Acute Poisoning\n",
      "- David SlessoronHEMOTION – transfusion thresholds in TBI\n",
      "- SBA 19 – FFICM PreponPROSEVA\n",
      "\n",
      "Heading: Special Themes\n",
      "List Items:\n",
      "- synergy physiotherapycliniconTEAM\n",
      "- Anand SwaminathanonANNEXA-I – Andexanet for Factor Xa Inhibitor–Associated ICH\n",
      "- Stuart McLayonNICO – Noninvasive Airway Management of Comatose Patients with Acute Poisoning\n",
      "- David SlessoronHEMOTION – transfusion thresholds in TBI\n",
      "- SBA 19 – FFICM PreponPROSEVA\n",
      "\n",
      "Heading: Subscribe to our newsletter\n",
      "List Items:\n",
      "- synergy physiotherapycliniconTEAM\n",
      "- Anand SwaminathanonANNEXA-I – Andexanet for Factor Xa Inhibitor–Associated ICH\n",
      "- Stuart McLayonNICO – Noninvasive Airway Management of Comatose Patients with Acute Poisoning\n",
      "- David SlessoronHEMOTION – transfusion thresholds in TBI\n",
      "- SBA 19 – FFICM PreponPROSEVA\n",
      "\n",
      "Heading: Subscribe to TBL Newsletters\n",
      "List Items:\n",
      "- synergy physiotherapycliniconTEAM\n",
      "- Anand SwaminathanonANNEXA-I – Andexanet for Factor Xa Inhibitor–Associated ICH\n",
      "- Stuart McLayonNICO – Noninvasive Airway Management of Comatose Patients with Acute Poisoning\n",
      "- David SlessoronHEMOTION – transfusion thresholds in TBI\n",
      "- SBA 19 – FFICM PreponPROSEVA\n",
      "\n",
      "Heading: Your data\n",
      "List Items:\n",
      "- synergy physiotherapycliniconTEAM\n",
      "- Anand SwaminathanonANNEXA-I – Andexanet for Factor Xa Inhibitor–Associated ICH\n",
      "- Stuart McLayonNICO – Noninvasive Airway Management of Comatose Patients with Acute Poisoning\n",
      "- David SlessoronHEMOTION – transfusion thresholds in TBI\n",
      "- SBA 19 – FFICM PreponPROSEVA\n",
      "\n",
      "Heading: Follow Us\n",
      "List Items:\n",
      "- synergy physiotherapycliniconTEAM\n",
      "- Anand SwaminathanonANNEXA-I – Andexanet for Factor Xa Inhibitor–Associated ICH\n",
      "- Stuart McLayonNICO – Noninvasive Airway Management of Comatose Patients with Acute Poisoning\n",
      "- David SlessoronHEMOTION – transfusion thresholds in TBI\n",
      "- SBA 19 – FFICM PreponPROSEVA\n",
      "\n",
      "Heading: Recent Comments\n",
      "List Items:\n",
      "- synergy physiotherapycliniconTEAM\n",
      "- Anand SwaminathanonANNEXA-I – Andexanet for Factor Xa Inhibitor–Associated ICH\n",
      "- Stuart McLayonNICO – Noninvasive Airway Management of Comatose Patients with Acute Poisoning\n",
      "- David SlessoronHEMOTION – transfusion thresholds in TBI\n",
      "- SBA 19 – FFICM PreponPROSEVA\n"
     ]
    }
   ],
   "source": [
    "import requests\n",
    "from bs4 import BeautifulSoup\n",
    "\n",
    "# Step 1: Fetch the webpage\n",
    "url = 'https://www.thebottomline.org.uk/summaries/icm/bling-iii/'\n",
    "response = requests.get(url)\n",
    "\n",
    "# Check if the request was successful\n",
    "if response.status_code == 200:\n",
    "    # Step 2: Parse the webpage content\n",
    "    soup = BeautifulSoup(response.content, 'html.parser')\n",
    "    \n",
    "    # Step 3: Extract the title\n",
    "    title_tag = soup.find('h1', class_='meta-article-title')\n",
    "    if title_tag:\n",
    "        title = title_tag.get_text(strip=True)\n",
    "        print(f\"Title: {title}\")\n",
    "    \n",
    "    # Step 4: Find all <h3> tags\n",
    "    headings = soup.find_all('h3')\n",
    "    \n",
    "    # Step 5: For each <h3> tag, find the next <ul> tag and extract the list items\n",
    "    for heading in headings:\n",
    "        print(f\"\\nHeading: {heading.get_text(strip=True)}\")\n",
    "        ul_tag = heading.find_next('ul')\n",
    "        if ul_tag:\n",
    "            list_items = [li.get_text(strip=True) for li in ul_tag.find_all('li')]\n",
    "            print(\"List Items:\")\n",
    "            for item in list_items:\n",
    "                print(f\"- {item}\")\n",
    "        else:\n",
    "            print(\"No list items found under this heading.\")\n",
    "else:\n",
    "    print(f\"Failed to retrieve the webpage. Status code: {response.status_code}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import scrapy\n",
    "from scrapy.linkextractors import LinkExtractor\n",
    "from scrapy.spiders import CrawlSpider, Rule\n",
    "\n",
    "class BottomlineSpider(CrawlSpider):\n",
    "    name = 'bottomline'\n",
    "    allowed_domains = ['thebottomline.org.uk']\n",
    "    start_urls = ['https://www.thebottomline.org.uk/summaries/icm/']\n",
    "\n",
    "    custom_settings = {\n",
    "        'CLOSESPIDER_PAGECOUNT': 2  # Limit to 2 pages\n",
    "    }\n",
    "\n",
    "    rules = (\n",
    "        Rule(LinkExtractor(allow=r'/summaries/icm/'), callback='parse_item', follow=True),\n",
    "    )\n",
    "\n",
    "    def parse_item(self, response):\n",
    "        title = response.xpath('//h1[@class=\"meta-article-title \"]/text()').get()\n",
    "        sections = response.xpath('//h3')\n",
    "        \n",
    "        data = {\n",
    "            'title': title,\n",
    "            'sections': []\n",
    "        }\n",
    "\n",
    "        for section in sections:\n",
    "            heading = section.xpath('text()').get()\n",
    "            items = section.xpath('following-sibling::ul[1]/li/text()').getall()\n",
    "            data['sections'].append({\n",
    "                'heading': heading,\n",
    "                'items': items\n",
    "            })\n",
    "\n",
    "        yield data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "nofrills",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.4"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
